BATF was identified as a key transcription factor that mediates NK-cell dysfunction in AML, implying that the adoptive transfer of allogeneic healthy NK cells in combination with TGF-β inactivation or BATF suppression might be a promising method for AML immunotherapy (7). The gene discussed is BATF; the disease is acute myeloid leukemia.